Gregory Harris, DO
Hematology & Oncology · Rome, GANPI 1568789261
Payments from drug & device makers
Across 115 payments — averaging $39.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$473
- AstraZeneca$353
- Lexicon Pharmaceuticals, Inc.$299
- Incyte Corporation$272
- GSK$248
- Beigene USA, Inc.$247
- plus $3K from 33 others
What the payments were for
- Speaking & faculty fees$1493%
- Food & beverage$3,87685%
- Education$55412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 10 | $473 |
| AstraZeneca | 7 | $353 |
| Lexicon Pharmaceuticals, Inc. | 1 | $299 |
| Incyte Corporation | 4 | $272 |
| GSK | 2 | $248 |
| Beigene USA, Inc. | 2 | $247 |
| Pfizer | 15 | $214 |
| Novartis | 9 | $193 |
| Puma Biotechnology, Inc. | 4 | $183 |
| Genentech USA, Inc. | 3 | $170 |
| Taiho Oncology, Inc. | 4 | $169 |
| Foundation Medicine, Inc. | 2 | $169 |
| Johnson & Johnson | 2 | $142 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Mirati Therapeutics, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $124 |
| Eisai Inc. | 6 | $110 |
| Lilly USA, LLC | 1 | $107 |
| Astellas Pharma US Inc | 5 | $102 |
| Exelixis Inc. | 2 | $93 |
| AbbVie | 3 | $79 |
| Sobi, Inc | 3 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $60 |
| Gilead | 3 | $56 |
| Merck | 2 | $54 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $44 |
| Bayer | 2 | $36 |
| Coherus Oncology, Inc. | 2 | $35 |
| Amgen | 2 | $33 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| Acrotech Biopharma Inc. | 1 | $28 |
| Sanofi | 1 | $23 |
| Mckesson Specialty Care Distribution, LLC | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| EUSA Pharma (US) LLC | 1 | $18 |
| Organon | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Array Biopharma Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xermelo$299
- BLENREP$248
- BRUKINSA$247
- FOUNDATIONONE$149
- FOUNDATIONONE HEME$149
- FOUNDATIONFOCUS$149
- FOUNDATIONONE CDX$149
- LYNPARZA$127
- TIVDAK$125
- Enhertu$125
- RYBREVANT$125
- KRAZATI$125
- MONJUVI$125
- NINLARO$124
- CALQUENCE$124
- INQOVI$124
- TUKYSA$124
- Nerlynx$123
- CYRAMZA$107
- VERZENIO$107
How this compares
$4,578 in reported general payments places this provider in the 40th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 103 | $1,867,677 |
| XtandiEnzalutamide | 109 | $1,492,864 |
| VerzenioAbemaciclib | 33 | $497,244 |
| PromactaEltrombopag Olamine | 13 | $456,346 |
| Lenalidomide | 23 | $330,924 |
| TasignaNilotinib Hcl | 14 | $288,999 |
| LenvimaLenvatinib Mesylate | 12 | $276,693 |
| IbrancePalbociclib | 13 | $195,529 |
| Abiraterone Acetate | 128 | $103,175 |
| Anastrozole | 256 | $4,442 |
| Cyclosporine ModifiedCyclosporine, Modified | 11 | $2,807 |
| Colestipol Hcl | 14 | $1,640 |
| Ondansetron Hcl | 142 | $1,419 |
| Scopolamine | 14 | $1,398 |
| Acyclovir | 75 | $1,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $102 | $1,492,864109 claims |
| NovartisPromacta, Tasigna | $193 | $745,34427 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $107 | $497,69570 claims |
| Eisai Inc.Lenvima | $110 | $276,69312 claims |
| PfizerIbrance | $214 | $195,52913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Rome
- Mehmet BilenAtlanta$21.7M
- Steven McCuneMarietta$19.5M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
- Amelia ZelnakCumming$4.4M
- Conor SteuerAtlanta$4.4M
- Anthony HunterAtlanta$4.3M
- Robert BrownAtlanta$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.